Wen Jiang
Department of Radiation Oncology, Division of Radiation Oncology
About Wen Jiang
Dr. Jiang joined the Department of Radiation Oncology as an Assistant Professor and Physician-Scientist in the CNS section. Dr. Jiang received his PhD in Bioengineering from the University of Toronto and his MD from Stanford University. He completed his residency training at MD Anderson Cancer Center in 2018. He subsequently joined UT Southwestern Medical Center as a tenure-track assistant professor of Radiation Oncology and a CPRIT Scholar. Dr. Jiang cares for patients with primary and secondary CNS tumors. His research focuses on the understanding of immune suppressive mechanisms within solid tumors and identifying novel therapeutic strategies to overcome immune escape. Dr. Jiang’s research is supported by CPRIT, NCI, NINDS, the Department of Defense and the Susan G. Komen Foundation.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | Stanford University, Stanford, CA, USA, MD, Medicine |
| 2008 | University of Toronto, Toronto, CAN, PHD, Biomedical Engineering |
| 2003 | Carleton University, Ottawa, CAN, BS, Electrical Engineering |
Board Certifications
| 2019 | American Board of Radiology |
Experience & Service
Academic Appointments
Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, 2018 - 2021
Honors & Awards
| 2019 | Circle of Friends Cancer Research Award, UT Southwestern |
| 2018 | Rising STARS Award, University of Texas System |
| 2018 | Scholar in Cancer Research, CPRIT |
| 2018 | A. Lavoy Moore Endowed Clinical Fellow, MD Anderson |
| 2018 | Jeffrey Lee Cousins Fellowship in Lung Cancer Research, MD Anderson |
| 2017 | Roentgen Resident/Fellow Research Award, RSNA |
| 2017 | Annual Meeting Travel Award, ASTRO |
| 2017 | Susan Papizan Dolan Fellowship in Breast Oncology, MD Anderson |
| 2017 | ASCO Young Investigator Award , Conquer Cancer Foundation |
| 2016 | Travel Award, RSNA Annual Meeting |
| 2016 | Research Resident Grant, RSNA Annual Meeting |
| 2016 | Workshop on Methods in Clinical Cancer Research, AACR/ASCO - Vail, CO |
| 2016 | Trainee Award - E.D. Montague Research Excellence Award, MD Anderson |
| 2015 | Trainee Award – Gilbert Fletcher Society Award, MD Anderson |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Huntoon K, Lee D, Dong S, Antony A, Kim BYS, Jiang W. Targeting phagocytosis to enhance antitumor immunity. Trends Cancer. e-Pub 2023. PMID: 37150626.
- Huntoon K, Jiang W, Kim BY. Waking immune-resistant tumors with neddylation. J Clin Invest 133(4), 2023. e-Pub 2023. PMID: 36787255.
- You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F, Kim BYS, Lee AS. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng. e-Pub 2023. PMID: 36635419.
- Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nat Nanotechnol 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
- Huntoon K, Anderson SK, Ballman KV, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross OA, Cerhan JH, Whitton AC, Greenspoon JN, Parney IF, Ashman JB, Bahary JP, Hadjipanayis C, Urbanic JJ, Farace E, Khuntia D, Laack NN, Brown PD, Roberge D, Kim BYS. Association of Circulating Markers with Cognitive Decline After Radiation Therapy for Brain Metastasis. Neuro Oncol. e-Pub 2022. PMID: 36472389.
- Li X, Khorsandi S, Wang Y, Santelli J, Huntoon K, Nguyen N, Yang M, Lee D, Lu Y, Gao R, Kim BYS, de Gracia Lux C, Mattrey RF, Jiang W, Lux J. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nat Nanotechnol 17(8):891-899, 2022. e-Pub 2022. PMID: 35637356.
- Li J, Xue C, Wang H, Dong S, Yang Z, Cao Y, Zhao B, Cheng B, Xie X, Mo X, Jiang W, Yuan H, Pan J. Hybrid Nanofibrous Composites with Anisotropic Mechanics and Architecture for Tendon/Ligament Repair and Regeneration. Small 18(27):e2201147, 2022. e-Pub 2022. PMID: 35686342.
- Hein DM, Deng W, Bleile M, Kazmi SA, Rhead B, De La Vega FM, Jones AL, Kainthla R, Jiang W, Cantarel B, Sanford NN. Racial and Ethnic Differences in Genomic Profiling of Early-Onset Colorectal Cancer. J Natl Cancer Inst 114(5):775-778, 2022. e-Pub 2022. PMID: 35134211.
- Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, Yang Y, Xu S, Yao H, Jiang W, Song E. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun 13(1):3011, 2022. e-Pub 2022. PMID: 35641481.
- Dong S, Bi Y, Sun X, Zhao Y, Sun R, Hao F, Sun Y, Wang Y, Li X, Deng W, Liu X, Ha J, Teng L, Gong P, Xie J, Kim BYS, Yang Z, Jiang W, Teng L. Dual-Loaded Liposomes Tagged with Hyaluronic Acid Have Synergistic Effects in Triple-Negative Breast Cancer. Small:e2107690. e-Pub 2022. PMID: 35277914.
- Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WF, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood SL, Powell SZ, Haviland DL, Parker Kerrigan BC, Lang FF, Prabhu SS, Huntoon KM, Jiang W, Kim BYS, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun 13(1):767, 2022. e-Pub 2022. PMID: 35140215.
- Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty K, Liu L, Wu K, Shay JW, Abdullah K, Zhang G, Ashley DM. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clin Cancer Res 27(24):6800-6814, 2021. e-Pub 2021. PMID: 34593527.
- Sun Z, Deng G, Peng X, Xu X, Liu L, Peng J, Ma Y, Zhang P, Wen A, Wang Y, Yang Z, Gong P, Jiang W, Cai L. Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. Biomaterials 279:121228, 2021. e-Pub 2021. PMID: 34717198.
- Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A 118(22), 2021. PMID: 34035167.
- Liu Y, Yang Z, Wang L, Sun L, Kim BYS, Jiang W, Yuan Y, Liu C. Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification-Mediated Bone Healing. Adv Sci (Weinh) 8(11):e2100143, 2021. e-Pub 2021. PMID: 34105266.
- Lee D, Huntoon K, Wang Y, Jiang W, Kim BYS. Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. Adv Mater:e2007576. e-Pub 2021. PMID: 34050699.
- Sun X, Yu K, Zhou Y, Dong S, Hu W, Sun Y, Li Y, Xie J, Lee RJ, Sun F, Ma Y, Wang S, Kim BYS, Wang Y, Yang Z, Jiang W, Li Y, Teng L. Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Appl Mater Interfaces. e-Pub 2021. PMID: 33764751.
- Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, da Veiga Leprevost F, Jaehnig EJ, Lei JT, Wen B, Schnaubelt M, Krug K, Song X, Cieslik M, Chang HY, Wyczalkowski MA, Li K, Colaprico A, Li QK, Clark DJ, Hu Y, Cao L, Pan J, Wang Y, Cho KC, Shi Z, Liao Y, Jiang W, Anurag M, Ji J, Yoo S, Zhou DC, Liang WW, Wendl M, Vats P, Carr SA, Mani DR, Zhang Z, Qian J, Chen XS, Pico AR, Wang P, Chinnaiyan AM, Ketchum KA, Kinsinger CR, Robles AI, An E, Hiltke T, Mesri M, Thiagarajan M, Weaver AM, Sikora AG, Lubinski J, Wierzbicka M, Wiznerowicz M, Satpathy S, Gillette MA, Miles G, Ellis MJ, Omenn GS, Rodriguez H, Boja ES, Dhanasekaran SM, Ding L, Nesvizhskii AI, El-Naggar AK, Chan DW, Zhang H, Zhang B, Clinical Proteomic Tumor Analysis Consortium. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39(3):361-379.e16, 2021. e-Pub 2021. PMID: 33417831.
- Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol 16(1):6-15, 2021. e-Pub 2020. PMID: 33349682.
- Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford NN, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Netw Open 3(12):e2028627, 2020. e-Pub 2020. PMID: 33295975.
- Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuv S, Iyengar P, Nedzi L, Hannan R, Anderson J, Choe KS, Jiang W, Abdulrahman R, Rahimi A, Folkert M, Laine A, Presley C, Cullum CM, Choy H, Ahn C, Timmerman R. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol 22(12):1831-1839, 2020. PMID: 32347302.
- Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral Immunotherapy for Early-stage Solid Tumors. Clin Cancer Res 26(13):3091-3099, 2020. e-Pub 2020. PMID: 32071116.
- Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res 26(7):1712-1724, 2020. e-Pub 2019. PMID: 31848190.
- von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun 11(1):1508, 2020. e-Pub 2020. PMID: 32198351.
- Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J, Lin S, Liu C, Jiang W, Qin S, Chen H, Huang Y. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. Int J Cancer 146(6):1730-1740, 2020. e-Pub 2019. PMID: 31840816.
- Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 4(1):69-83, 2020. e-Pub 2019. PMID: 31844155.
- Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19(10):568-586, 2019. e-Pub 2019. PMID: 31462760.
- Liu Z, Wang Y, Huang Y, Kim BYS, Shan H, Wu D, Jiang W. Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends Pharmacol Sci 40(9):613-623, 2019. e-Pub 2019. PMID: 31331639.
- Li N, Wang Y, Neri S, Zhen Y, Fong LWR, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun 10(1):4363, 2019. e-Pub 2019. PMID: 31554794.
- Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 25(6):1709-1717, 2019. e-Pub 2018. PMID: 30413527.
- Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, Zhao L, Teo HY, Qiu J, Jiang W, Dong C, Wu D, Huang Y, Liu H. NCR- group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine 41:333-344, 2019. e-Pub 2019. PMID: 30827928.
- Chen Y, Liu X, Yuan H, Yang Z, von Roemeling CA, Qie Y, Zhao H, Wang Y, Jiang W, Kim BYS. Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Adv Sci (Weinh) 6(5):1802070, 2019. e-Pub 2019. PMID: 30886813.
- Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24(22):5744-5756, 2018. e-Pub 2018. PMID: 30068711.
- Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating Nanomedicine for Cancer Therapy. Nano Lett 18(11):6655-6659, 2018. e-Pub 2018. PMID: 30185039.
- Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
- Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 18(3):195-203, 2018. e-Pub 2018. PMID: 29332937.
- Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res 24(2):341-350, 2018. e-Pub 2017. PMID: 29030353.
- Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8(1):1811, 2017. e-Pub 2017. PMID: 29180759.
- Chow KH, Park HJ, George J, Yamamoto K, Gallup AD, Graber JH, Chen Y, Jiang W, Steindler DA, Neilson EG, Kim BYS, Yun K. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Res 77(19):5360-5373, 2017. e-Pub 2017. PMID: 28807938.
- Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat Nanotechnol 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
- Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS. Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nat Rev Drug Discov 16(6):369-370, 2017. e-Pub 2017. PMID: 28303024.
- von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends Biotechnol 35(2):159-171, 2017. e-Pub 2016. PMID: 27492049.
- Jiang W, von Roemeling C, Qie Y, Chen Y, Liu X, Chen J, Kim BYS. Designing next generation cancer nano medicine for immuno-oncology. Nature Biomedical Engineering 1:0029, 2017.
- Jiang W, Chan CK, Weissman IL, Kim BYS, Hahn SM. Immune Priming of the Tumor Microenvironment by Radiation. Trends Cancer 2(11):638-645, 2016. e-Pub 2016. PMID: 28741502.
- Jiang W, Huang Y, An Y, Kim BY. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9):8689-96, 2015. e-Pub 2015. PMID: 26212564.
- Chan CK, Lindau P, Jiang W, Chen JY, Zhang LF, Chen CC, Seita J, Sahoo D, Kim JB, Lee A, Park S, Nag D, Gong Y, Kulkarni S, Luppen CA, Theologis AA, Wan DC, DeBoer A, Seo EY, Vincent-Tompkins JD, Loh K, Walmsley GG, Kraft DL, Wu JC, Longaker MT, Weissman IL. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proc Natl Acad Sci U S A 110(31):12643-8, 2013. e-Pub 2013. PMID: 23858471.
- Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popovic Z, Jain RK, Bawendi MG, Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A 108(6):2426-31, 2011. e-Pub 2011. PMID: 21245339.
- Liu W, Greytak AB, Lee J, Wong CR, Park J, Marshall LF, Jiang W, Curtin PN, Ting AY, Nocera DG, Fukumura D, Jain RK, Bawendi MG. Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J Am Chem Soc 132(2):472-83, 2010. PMID: 20025223.
- Kim BY, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett 8(11):3887-92, 2008. e-Pub 2008. PMID: 18816147.
- Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145-50, 2008. e-Pub 2008. PMID: 18654486.
- Lee D, Huntoon K, Lux J, Kim BYS, Jiang W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nature Reviews Bioengineering.
Invited Articles
- Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufés C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol 14(7):629-635, 2019. PMID: 31270452.
Editorials
- Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. JAMA Oncol 4(8):1116-1117, 2018. PMID: 29327039.
- Jiang W. A tale of two disciplines. Nat Nanotechnol 11(8):732, 2016. PMID: 27485586.
Grant & Contract Support
| Title: | First time, tenure track faculty recruitment award |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | Engaging the Immune System to Improve Metastatic Breast Cancer Treatment |
| Funding Source: | Susan G. Komen Foundation |
| Role: | Principal Investigator |
| Title: | A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody |
| Funding Source: | NIH/NINDS |
| Role: | Principal Investigator |
| Title: | Ultrasound-Guided Targeted STING Activation for Breast Cancer Immunotherapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | Principal Investigator |
| Title: | 6-thio-deoxyguanosine: A Novel Immunogenic Telomerase-mediated Therapy in Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Treating Metastatic Cancer using Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | Circulating Exosome-Based Biomarker for Treatment Monitoring in Anal Cancer |
| Funding Source: | Radiation Oncology Institute |
| Role: | Principal Investigator |
| Title: | Bridging Innate and Adaptive Glioblastoma Immunity via Phagocytosis Checkpoint Blockade |
| Funding Source: | American Brain Tumor Association |
| Role: | Principal Investigator |
| Title: | UT Rising Stars Award |
| Funding Source: | University of Texas Systems |
| Role: | Principal Investigator |
| Title: | High throughput multiplexed immunological profiling of glioblastoma |
| Funding Source: | ASCO/Conquer Cancer Foundation |
| Role: | Principal Investigator |
| Title: | Combining chemoradiation with anti-phosphatidylserine blockade promotes immunogenic phagocytosis to generate long-lasting anti-tumor immunity |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | Principal Investigator |
| Title: | Glioblastoma immunotherapy with dual phagocytosis checkpoint blockade |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Principal Investigator |
| Title: | Eliciting abscopal effect of combined radiotherapy, PD-1 blockade and NL-201 in localized and metastatic cancers |
| Funding Source: | Neoleukin Inc |
| Role: | Principal Investigator |